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Introduction {#sec1}
============

Reversible covalent modification of proteins with the small ubiquitin-like modifier (SUMO) is critical for the viability of eukaryotic cells by affecting protein interactions, sub-cellular localization, and activity ([@bib19]). SUMO is conjugated to acceptor lysines on the surface of its substrates in the form of monomers, leading to monoSUMOylation or multiSUMOylation when several target lysines are modified. SUMOylation frequently targets entire protein groups actively engaged in common functions ([@bib27], [@bib43]). Moreover, various proteins contain SUMO-interacting motifs (SIMs) with which they can engage in non-covalent interactions with SUMO ([@bib53]), stabilizing protein assemblies. Similar to ubiquitin, SUMO can form polymeric chains via different linkages, leading to substrate polySUMOylation; however, functional insights into the role of SUMO chains are limited ([@bib19], [@bib54], [@bib57]). Both mono- and/or multiSUMOylation and polySUMO chains can be further recognized by ubiquitin E3 ligases containing single or multiple SIMs. These ubiquitin ligases, known as SUMO-targeted ubiquitin ligases (STUbLs), can mediate proteolytic or non-proteolytic ubiquitylation of the SUMO-modified substrate ([@bib55]). The outcome depends, in manners that remain largely to be deciphered, on both the substrate and the STUbL involved. Moreover, ubiquitin and SUMO attached to the substrate can cooperate to recruit downstream factors, such as the Cdc48/p97 ATPase ([@bib3], [@bib13], [@bib35]), that decide the fate of the modified substrate.

SUMO chains are thought to have signaling functions in the cell, as for synaptonemal complex assembly in budding yeast meiosis ([@bib10]) and replication arrest response in fission yeast ([@bib52]). SUMO chains have also been suggested to play roles in chromatin regulation, including maintenance of higher-order chromatin structure and transcriptional repression of environmental stress response genes in budding yeast ([@bib54]). This is likely based on the ability of SUMO chains to attract various SIM-containing factors or STUbLs or become disassembled by specific SUMO proteases; namely, SENP6/SENP7 in mammalian cells and Ulp2 in budding yeast ([@bib7], [@bib15], [@bib23]). However, the role of SUMO chains in signaling remains largely enigmatic, and much remains to be understood about the identity of SUMO substrates that require SUMO chains for proteasomal degradation or other functions.

Here we attempted to address the molecular function of SUMO chains by focusing on the budding yeast SUMO protease Ulp2, which provides the main SUMO-chain-depolymerizing activity in this organism. Using a yeast two-hybrid (Y2H) screen, we identified Dbf4, the DNA-binding subunit of Dbf4-dependent kinase (DDK), which mediates DNA replication initiation by phosphorylating the replicative helicase MCM (minichromosome maintenance protein complex) ([@bib2]), as an interactor of Ulp2. We uncovered that Ulp2 is enriched at replication origins and that its loss leads to inefficient replication onset, which can be rescued by concomitant inactivation of the Slx5/8 STUbL. We found that a critical substrate for Ulp2 and Slx5/8 in this process is DDK itself. Both subunits of DDK, Dbf4 and Cdc7, which are actively engaged in replication, become SUMOylated on chromatin. Ulp2 protects mono- and/or multiSUMOylated DDK against Slx5/8-mediated proteasomal degradation by binding to growing SUMO chains via multiple SIMs located in its N terminus and trimming them from the distal ends. The proteasome-mediated turnover of SUMOylated DDK is assisted by the Cdc48 segregase and strictly depends on SUMO chains that are counteracted by Ulp2. Importantly, the SUMOylation-defective *ddk-KR* mutant, in which major SUMO acceptor lysines are replaced with arginines on both Dbf4 and Cdc7, suppresses the replication onset defects and rescues reduced Mcm4 phosphorylation and slower S phase progression of the *ulp2*Δ mutant. Altogether, the results indicate that Ulp2 allows critical levels of mono- and/or multiSUMOylated DDK to be locally concentrated at origins of replication, making efficient onset of replication possible. Using two unbiased Slx5/8 ubiquitin ligase substrate trapping and stable isotope labeling with amino acids in cell culture (SILAC)-based proteomic screens, we further identify subunits of the MCM helicase and other factors as potential SUMO-chain-modified degradation-prone substrates of Ulp2 and Slx5/Slx8. We propose that SUMO-chain- and Ulp2-protease-regulated proteasomal degradation acts as a fate maker of protein availability at replication origins and, possibly, in other replication and cellular contexts.

Results {#sec2}
=======

The SUMO Protease Ulp2 Binds to Dbf4 and Is Enriched at Replication Origins {#sec2.1}
---------------------------------------------------------------------------

In a Y2H screen using the Ulp2 SUMO protease as bait, we identified the Dbf4 subunit of DDK and the Polo-like kinase Cdc5 as Ulp2 interactors ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Because Ulp2 has been reported previously to interact with and be negatively regulated by Cdc5 in mitosis ([@bib1]), here we pursued the interaction between Ulp2 and Dbf4, which we further confirmed by Y2H analysis in both orientations ([Figure S1](#mmc1){ref-type="supplementary-material"}B). We used catalytically dead transcription activation domain (AD)-fusion and DNA-binding domain (BD)-fusion of Ulp2 (Ulp2-C624S; Ulp2~CD~), which we envisaged to interact stronger with potential substrates based on previous work on Ulp1~CD~, which behaved like a SUMO substrate trap ([@bib16]). To examine whether Ulp2 binds to chromatin and map its clusters, we used genome-wide chromatin immunoprecipitation (ChIP) studies (ChIP-on-chip) in G1-arrested and hydroxyurea (HU)-treated wild-type (WT) cells expressing endogenously tagged Ulp2-PK. Multiple chromatin-bound clusters of Ulp2 were detected across the genome under both conditions. Importantly, we found that Ulp2 binds to autonomously replicating sequence (ARS) regions marking origins of replication in both G1 and S phase ([Figure 1](#fig1){ref-type="fig"}A) in a manner that is statistically significant (p = 5.1E−19 and p = 5.6E−67 for G1 and S, respectively). The peaks of Ulp2 proximal to early ARS regions were wider in HU-treated cells compared with G1 ([Figure 1](#fig1){ref-type="fig"}A), indicating spreading of Ulp2 around active replication origins. A nearly identical profile of Ulp2 binding to chromatin was observed with the endogenously tagged Ulp2-FLAG strain ([Figure S1](#mmc1){ref-type="supplementary-material"}C).Figure 1The SUMO Protease Ulp2 Is Enriched at Replication Origins(A) ChIP-on-chip profiles of Ulp2-PK from G1-arrested cells following their release in the presence of 0.2 M HU for 90 min. A fragment of chromosome 3 is shown as an example (left). The p value is related to the genome-wide overlap between Ulp2-PK clusters under the two conditions. Average Ulp2-PK binding profiles in a window of 12 kbp centered at each of the 141 active ARSs are shown (right).(B) Overlapping BrdU IP-on-chip profile (orange) and ChIP-on-chip profile of Ulp2-PK (green) from cells released in the presence of 0.2 M HU and BrdU for 90 min after G1 arrest.(C) ChIP-on-chip profiles of Ulp2-PK from wild-type (WT) cells and cells with the indicated ARSs deleted (*ars*Δ).See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We further found genome-wide statistically significant overlap between Ulp2 and bromodeoxyuridine (BrdU) clusters that mark ongoing replication, with both Ulp2 and BrdU peaks centered on origins of replication in cells released from G1 arrest into HU- and BrdU-containing media ([Figure 1](#fig1){ref-type="fig"}B). Moreover, when cells were released from HU arrest into medium containing BrdU, Ulp2 peaks became broader compared with those in HU ([Figure S1](#mmc1){ref-type="supplementary-material"}D), indicating that Ulp2 may bind replication fork components. Supportive of this, we found, by co-immunoprecipitation (coIP), that Ulp2 interacts with the Mcm4 subunit of the MCM helicase ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

To address whether Ulp2 binding to replicating regions depends on ARS elements, we used a strain in which three early ARS regions in chromosome 6 were abolished (*ars*Δ strain) ([@bib14]). Ulp2 binding specifically to the mutated ARS regions was lost ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}F). Regarding the potential mechanism implicated in Ulp2 recruitment, we found that yeast SUMO N-terminally tagged with FLAG (FLAG-SUMO) was also enriched at replicating regions incorporating BrdU ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Altogether, the results suggest that Ulp2 is recruited to replication origins, likely by its ability to recognize SUMOylated replisome factors.

Ulp2 Allows Efficient Replication Onset by Counteracting Slx5/8 STUbL {#sec2.2}
---------------------------------------------------------------------

To determine the consequences of Ulp2 recruitment to replication origins, we examined, by 2D DNA gel electrophoresis, the profile of replication intermediates formed at an early efficient origin of replication, ARS305, when G1-arrested cells were synchronously released in HU-containing medium. The density of replication intermediates, bubbles and Y-arcs, was reduced in *ulp2*Δ cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Moreover, we observed reduced BrdU incorporation efficiency in *ulp2*Δ genome-wide ([Figures 2](#fig2){ref-type="fig"}A and 2B) and at ARS305 measured by BrdU immunoprecipitation (IP)-qPCR ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Thus, *ulp2*Δ cells have reduced efficiency in origin firing and/or early steps of DNA replication elongation.Figure 2Ulp2 Supports Efficient Replication Onset by Counteracting the SUMO-Targeted Ubiquitin Ligase Slx5/8(A) The decrease in BrdU incorporation in *ulp2*Δ is suppressed by deleting *SLX5*. Shown are BrdU IP-on-chip profiles from WT, *ulp2*Δ, and *ulp2*Δ *slx5*Δ cells released from G1 arrest in the presence of 0.2 M HU for 90 min.(B) Average BrdU incorporation profiles in cells from (A) in a window of 24 kbp centered at each of the 141 active ARSs.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Ulp2 has a preference for substrates modified with SUMO chains, which Ulp2 cleaves sequentially from the chain end ([@bib15]). Importantly, SUMOylation of certain substrates can be recognized by STUbLs that can ubiquitylate the substrate, targeting it for proteasomal degradation ([@bib55]). Because some phenotypes of *ulp2*Δ cells are alleviated by concomitant deletion of heterodimeric Slx5/8 STUbL ([@bib39]), we examined whether the replication defects associated with Ulp2 loss are compensated upon inactivation of Slx5/8 by comparing the genome-wide BrdU incorporation profiles in *ulp2*Δ and *ulp2*Δ *slx5*Δ ([Figure 2](#fig2){ref-type="fig"}A). Averaging the BrdU incorporation profiles around 141 active replication origins revealed that the *ulp2*Δ mutation particularly affects the spreading of BrdU around ARS regions and that *slx5*Δ suppressed this phenotype ([Figure 2](#fig2){ref-type="fig"}B). These data suggest that the replication defect of *ulp2*Δ may be caused by the Slx5/8 STUbL-mediated proteasomal degradation of certain SUMOylated factor(s) required for early steps of DNA replication.

DDK Engaged in Replication Is SUMOylated and Protected by Ulp2 against Slx5/8 STUbL {#sec2.3}
-----------------------------------------------------------------------------------

We sought to validate the Ulp2 Y2H interaction with Dbf4 ([Figure S1](#mmc1){ref-type="supplementary-material"}B) using coIP. Therefore, we C-terminally tagged endogenous Dbf4 and Ulp2 with PK and FLAG tags, respectively. Initial IP with the anti-FLAG antibody revealed that Ulp2-FLAG interacts with Dbf4-PK and has a preference for upshifted, potentially SUMO-modified forms of Dbf4-PK ([Figure S3](#mmc1){ref-type="supplementary-material"}A). These slower-migrating species of Dbf4-PK were specifically immunoprecipitated with the anti-PK antibody but not mouse immunoglobulin G (IgG) ([Figure S3](#mmc1){ref-type="supplementary-material"}B). To directly address whether Dbf4 is SUMOylated, we performed pull-down of all SUMO conjugates present in the cell under fully denaturing conditions and probed for Dbf4. The employed strains had the endogenous yeast SUMO (Smt3) N-terminally tagged with a 7His tag (^His^SUMO) so that SUMOylated species were enriched by nickel-nitrilotriacetic acid (Ni-NTA) pull-down (Ni PD) ([@bib43], [@bib44]). We engineered cells that express N-terminally 3x hemagglutinin epitope tag (3HA)-tagged Dbf4 either under the control of the endogenous *DBF4* promoter (*pDBF4*) or a strong constitutive *ADH1* promoter (*pADH1*). Slower-migrating forms of ^3HA^Dbf4 were specifically detected in cells expressing ^His^SUMO and were more abundant when *DBF4* was overexpressed ([Figure 3](#fig3){ref-type="fig"}A). Thus, Dbf4 is SUMOylated.Figure 3Chromatin-Bound DDK Engaged in Replication Is SUMOylated and Protected by Ulp2 against Slx5/8 STUbL-Mediated Proteasomal Degradation(A) Dbf4 is SUMOylated. Shown is denaturing Ni-NTA pull-down (Ni PD) of ^His^SUMO conjugates from cells expressing ^3HA^Dbf4 under the control of an endogenous (*pDBF4*) or strong constitutive *ADH1* promoter (*pADH1*).(B) Dbf4 SUMOylation is increased in the absence of the Rad53 checkpoint. Shown is ^His^SUMO Ni PD from *sml1*Δ and *sml1*Δ *rad53*Δ cells or untreated cells grown to an optical density of a sample at 600 nanometers (OD~600~) of 0.7 and then shifted to 0.2 M HU for 90 min. Ni PD efficiency was assayed using an anti-Smt3 antibody and staining with Ponceau S. Asterisks denote cross-reactivity of the anti-HA antibody.(C) Artificial targeting of Dbf4 to DNA triggers its SUMOylation; as in (B), but with WT cells expressing either ^3HA^Dbf4 or its BD~60~ and BD~120~ fusions.(D) Artificial DNA targeting of Dbf4 triggers SUMOylation of the DDK catalytic subunit Cdc7; as in (C), but with cells expressing either untagged Cdc7 or Cdc7^9PK^.(E) SUMOylated Dbf4 species accumulate in the *cim3-1* proteasome-defective mutant but not in *cim3-1 ulp2*Δ; as in (B), but with WT, *ulp2*Δ, *cim3-1*, and *cim3-1 ulp2*Δ cells.(F) Decreased levels of SUMOylated Dbf4 in *cim3-1 ulp2*Δ cells are restored in the *cim3-1 ulp2*Δ *slx5*Δ mutant; as in (E), but with *cim3-1*, *cim3-1 ulp2*Δ, *cim3-1 slx5*Δ, and *cim3-1 ulp2*Δ *slx5*Δ cells.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

We next inquired about the functional context in which Dbf4 undergoes SUMOylation. DDK is required for activation of all origins, but late origin firing is inhibited by the Mrc1-Rad53 checkpoint ([@bib8], [@bib42], [@bib46]). Ni PD in *sml1*Δ and *rad53*Δ *sml1*Δ strains (*sml1*Δ allows viability of *rad53*Δ cells) revealed that Rad53 loss caused an increase in Dbf4 SUMOylation irrespective of HU treatment ([Figure 3](#fig3){ref-type="fig"}B). Thus, rather than being induced at stalled and collapsed forks, SUMOylation engages the chromatin-bound DDK pool acting at replication origins. Similar results were observed in the *mrc1*Δ mutant ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

To probe the importance of Dbf4 being associated with chromatin for its SUMOylation, we induced artificial DNA targeting of Dbf4 by fusing two forms of the Gal4 transcription factor DNA-binding domain to the N terminus of Dbf4 expressed from the *ADH1* promoter. One is a dimerization- and DNA binding-proficient variant spanning the 1--120 amino acids of Gal4 (BD~120~), and the other is a dimerization- and DNA binding-defective variant spanning the 1--60 amino acids (BD~60~) ([@bib37]). Ni PD assays revealed that specifically the BD~120~ fusion induces Dbf4 SUMOylation ([Figure 3](#fig3){ref-type="fig"}C). When Dbf4 was targeted to chromatin, we also detected increased SUMOylation of endogenous Cdc7 tagged C-terminally with a 9PK tag ([Figure 3](#fig3){ref-type="fig"}D). Thus, both Dbf4 and Cdc7 are SUMOylated when performing their function on chromatin.

To address whether SUMOylated DDK becomes a degradation-prone substrate of Slx5/8 STUbL that has to be protected by Ulp2 to fulfill its functions, we performed Ni PD using a temperature-sensitive *cim3-1* proteasome-defective mutant under the permissive temperature of 28°C, at which proteasomal substrates are partially stabilized. The experiments revealed strong accumulation of SUMOylated ^3HA^Dbf4 and ^3HA^Cdc7 species in the *cim3-1* background compared with the WT but not of their unmodified forms ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}D), suggesting that specifically the SUMOylated DDK pool becomes susceptible to proteasomal degradation. Moreover, SUMOylated Dbf4 and Cdc7 species accumulating in *cim3-1* required Ulp2 for stabilization ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}E). In the absence of Ulp2, high-molecular-weight (HMW) SUMO conjugates accumulate ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}E; see input with HMW ^His^SUMO conjugates; [@bib7], [@bib56]). These HMW SUMO conjugates were not detected in the corresponding Ni PD, suggesting that they are lost during the pull-down procedure. This likely explains both the apparent decrease in Ni PD efficiency of ^His^SUMO conjugates from *ulp2*Δ cells and the inability to detect SUMO-chain-modified Dbf4 and Cdc7 in *cim3-1 ulp2*Δ cells. Importantly, the decreased levels of degradation-prone SUMOylated Dbf4 in *cim3-1 ulp2*Δ cells were restored in *cim3-1 ulp2*Δ *slx5*Δ cells ([Figure 3](#fig3){ref-type="fig"}F), suggesting that Ulp2 protects mono- and/or multiSUMOylated DDK against Slx5/8 STUbL-mediated turnover.

SUMO Chains Target DDK for Slx5/8 STUbL-Mediated Proteasomal Degradation {#sec2.4}
------------------------------------------------------------------------

We next asked whether any of the three known SUMO ligases operating in mitotic yeast cells---Siz1, Siz2, and Mms21---mediate DDK SUMOylation. ^His^SUMO Ni PD revealed that *siz1*Δ and *siz2*Δ mutants, but not the *mms21-11* mutant defective in its SUMO ligase activity, had lower levels of SUMOylated Cdc7 and Dbf4 compared with the WT ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A). Thus, DDK is being SUMOylated by Siz1 and Siz2, both of which harbor DNA-binding SAF-A/B, Acinus, PIAS (SAP) domains ([@bib27]).Figure 4Ulp2 Counteracts Siz1/2-Mediated SUMO Chain Formation, which Targets SUMOylated DDK for Cdc48 ATPase-Assisted Proteasomal Degradation(A) SUMOylation of Cdc7 is mediated by the SUMO ligases Siz1 and Siz2. Shown is ^His^SUMO Ni PD from the *cim3-1* mutant expressing ^3HA^Cdc7 (WT) and cells additionally lacking the SUMO ligase Siz1, Siz2, or both or carrying the *mms21-11* allele.(B) The decreased levels of SUMOylated Dbf4 species in *cim3-1 ulp2*Δ are restored when, instead of ^His^SUMO, a lysine-less SUMO variant (*KRall*) is expressed.(C) ^His^SUMO Ni PD from WT cells and a temperature-sensitive *cdc48-6* mutant expressing ^3HA^Dbf4 under the control of an endogenous promoter (*pDBF4*), grown to an OD~600~ of 0.7 at 28°C and then shifted to 37°C for 3 h. SUMOylated Dbf4 species accumulate in the *cdc48-6* mutant compared with WT cells.(D) Dbf4 interacts in Y2H with Siz2, Slx5, and Ulp2 (catalytically dead Ulp2-C624S; Ulp2~CD~) but not with its N-terminally truncated variant Ulp2~CD~-N~400~. Like Dbf4, Cdc48 interacts with Ulp2 depending on its N terminus. 8 mM 3-amino-triazole (3-AT) was added to reduce auto-activation of the *HIS3* reporter gene.(E) Interaction of Dbf4 with Siz2, Slx5, and Ulp2 is lost in the absence of Siz1 and Siz2. Dbf4 binding to Siz2 is Siz1-dependent.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

We next investigated whether SUMO chains are indeed the signal for the STUbL-mediated proteasomal degradation of DDK. We performed Ni PD in *cim3-1* cells expressing, as a single source of SUMO, either ^His^SUMO or a His-tagged SUMO variant in which all lysine residues were mutated to arginine (*KRall*), preventing formation of lysine-linked SUMO chains. Expressing the *KRall* SUMO mutant abolished the accumulation of HMW ^His^SUMO conjugates in *ulp2*Δ cells, increased the abundance of mono- and/or multiSUMOylated Dbf4 and Cdc7 species in the WT, and suppressed their instability in *ulp2*Δ cells ([Figures 4](#fig4){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}B). Thus, SUMO chains target replication-engaged SUMOylated DDK for Slx5/8 STUbL-mediated proteasomal degradation in the absence of Ulp2.

The Cdc48/p97 ATPase emerged as an important regulator of SUMO and ubiquitin conjugates on chromatin, often in collaboration with STUbLs ([@bib3], [@bib29]). First, we found Y2H interaction between Dbf4 and the Cdc48 substrate-recruiting co-factor Ufd1 ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Next, using the temperature-sensitive *cdc48-6* and *cdc48-3* mutants, we observed an accumulation of SUMOylated Dbf4 species following Cdc48 inactivation ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}D). Thus, Cdc48 segregase assists with turnover of SUMOylated DDK.

Further confirming the uncovered links between components of the SUMO and ubiquitin pathways and DDK, we observed binding of Dbf4 to the SUMO ligase Siz2 and the Slx5 subunit of the Slx5/8 STUbL by Y2H ([Figure 4](#fig4){ref-type="fig"}D). Moreover, Y2H revealed binding of Ulp2 to Cdc48, which was dependent on the N terminus (amino acids \[aa\] 1--400) of Ulp2. Similarly, N-terminally truncated, catalytically inactive Ulp2 (Ulp2~CD~-N~400~) failed to interact with Dbf4 in both orientations ([Figure 4](#fig4){ref-type="fig"}D), indicating that Ulp2 uses certain motif(s) at its N terminus for binding to its SUMOylated substrates. Supporting this notion, we observed loss of Dbf4 binding to Ulp2 but also to Siz2 and Slx5 when both SUMO ligases, Siz1 and Siz2, responsible for SUMOylation of DDK were deleted in the Y2H reporter strain ([Figure 4](#fig4){ref-type="fig"}E). Dbf4 binding to Siz2 thus seems to be Siz1-dependent. The presence of Siz2, in turn, is largely required for the interaction between Dbf4 and both Slx5 and Ulp2 and also between Cdc48 and Ulp2 ([Figure S4](#mmc1){ref-type="supplementary-material"}E).

N-Terminal SUMO-Interacting Motifs of Ulp2 Mediate Binding to and Protection of SUMOylated DDK {#sec2.5}
----------------------------------------------------------------------------------------------

Regarding how Ulp2 is recruited to mono- and/or multiSUMOylated DDK that it protects, we found that artificial targeting of DDK to Gal4-binding sites using the BD~120~-Dbf4 fusion ([Figures 3](#fig3){ref-type="fig"}C and 3D) causes concomitant recruitment of Ulp2 specifically to the genes of the yeast galactose regulon ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Thus, SUMOylated DDK is capable of directly recruiting Ulp2 to chromatin even when DDK is not in the context of the replisome, suggesting how Ulp2 might become enriched at replication origins.

Next, following the observed loss in binding of Dbf4 to the truncated variant Ulp2~CD~-N~400~ in Y2H ([Figure 4](#fig4){ref-type="fig"}D), we examined whether this region contains putative SIMs, short hydrophobic sequences that mediate binding to SUMO ([@bib53]). Interestingly, we found potential SIMs in Ulp2 that strongly resemble validated N-terminal SIMs of the Slx5 STUbL subunit ([@bib60]), both in number and relative positioning ([Figure 5](#fig5){ref-type="fig"}A). When we abolished either the first three (*ulp2-sim1,2,3*) or all five (*ulp2-sim1,2,3,4,5*) potential N-terminal SIMs in Ulp2 by replacing hydrophobic residues with alanines, the interaction of Dbf4 with Ulp2 in Y2H was lost, similar to the N-terminally truncated variant Ulp2~CD~-N~400~ ([Figure 5](#fig5){ref-type="fig"}B). We next recombinantly expressed the N terminus of Ulp2 as glutathione S-transferase (GST) fusion (GST-Ulp2~1-400~) and found that it indeed interacts with both recombinant free yeast Smt3 (^His^SUMO) and human poly-SUMO3 chains *in vitro* ([Figures 5](#fig5){ref-type="fig"}C and 5D). Strikingly, the N terminus of Ulp2 shows a strong preference for binding poly-SUMO3 chains longer than 5 SUMO3 units ([Figure 5](#fig5){ref-type="fig"}D), in line with the idea that Ulp2 recognizes its SUMO-chain-modified substrates via its five N-terminal SIMs. To address whether the identified putative SIMs are important for SUMO binding, we recombinantly expressed the GST-Ulp2~1--400~ fragments with *sim1,2,3* and *sim1,2,3,4,5* mutations. These variants, when expressed in *E. coli*, showed more degradation products that also retained the ability to bind free SUMO ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Importantly, however, when adjusted for the overall GST signal, the GST-Ulp2~1-400~ fusions with SIMs mutated showed strongly reduced (almost to the background level in the case of *sim1,2,3,4,5)* binding to SUMO compared with WT GST-Ulp2~1--400~ ([Figure S5](#mmc1){ref-type="supplementary-material"}C).Figure 5SUMO-Interacting Motifs at the N terminus of Ulp2 Mediate Binding to Dbf4 and Are Required to Protect SUMOylated DDK from Proteasomal Turnover(A) Predicted SIMs in the Ulp2 N terminus resemble confirmed Slx5 SIMs in number and relative positioning (highlighted green). Shown is a schematic representation of Slx5 and Ulp2 with the RING and protease domains, SIMs (blue), and introduced mutations (red) that disrupt potential SIMs.(B) Y2H interaction of Dbf4 with Ulp2 is abolished when either first three or all five N-terminal putative SIMs of Ulp2 are mutated, similar to Ulp2~CD~-N~400~.(C and D) Recombinant GST fusion of the Ulp2 N terminus (aa 1--400) binds both yeast-free SUMO (C) and human poly-SUMO3 chains (D) *in vitro*, with a stronger preference for chains having more than 5 SUMO3 moieties.(E) *ulp2-sim* mutants phenotypically resemble *ulp2*Δ cells regarding slow growth and temperature sensitivity but have lower sensitivity to HU.(F) Both *ulp2-sim* mutants similar to *ulp2*Δ fail to protect SUMOylated Dbf4 against SUMO chain/STUbL-mediated proteasomal degradation. Shown is ^His^SUMO Ni PD from *cim3-1*, *cim3-1 ulp2*Δ, and *cim3-1* cells carrying either Ulp2^9PK^ or its SIM mutant variants.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

*In vivo*, *ulp2-sim* mutants phenotypically resembled *ulp2*Δ cells regarding slow growth and temperature sensitivity. However, both *ulp2-sim* mutants showed lower sensitivity to HU compared with *ulp2*Δ, and *ulp2-sim1,2,3* had milder phenotypes compared with *ulp2-sim1,2,3,4,5*, suggestive of residual protease activity toward SUMO conjugates ([Figure 5](#fig5){ref-type="fig"}E). Finally, we asked whether the identified N-terminal SIMs of Ulp2 are required for protection of mono- and/or multiSUMOylated DDK against STUbL-mediated proteasomal turnover. Both *ulp2-sim* mutants failed to protect mono- and/or multiSUMOylated Dbf4 ([Figure 5](#fig5){ref-type="fig"}F) and Cdc7 ([Figure S5](#mmc1){ref-type="supplementary-material"}D) against proteasomal degradation and accumulated HMW ^His^SUMO conjugates, similar to the *ulp2*Δ mutant, despite being expressed at WT levels. Thus, Ulp2 protects replication-engaged mono- and/or multiSUMOylated DDK against Slx5/8-mediated proteasomal degradation by binding to growing SUMO chains via five SIMs located in its N terminus and trimming them from the distal ends.

Ulp2 Safeguards SUMOylated DDK, Allowing Replication Initiation {#sec2.6}
---------------------------------------------------------------

We next addressed what the functional consequence would be for cells of losing the Ulp2-mediated protection of the SUMOylated DDK pool engaged in replication. First, using a genetic approach, we found that *ulp2*Δ has synergistic growth defects with temperature-sensitive mutations in DDK, such as *dbf4-1*, *cdc7-4*, and *cdc7-1*, at temperatures permissive for the single mutants ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S6](#mmc1){ref-type="supplementary-material"}A), suggesting that, in the absence of Ulp2, DDK function is further compromised in these mutants. Importantly, the above-mentioned synthetic lethality of *dbf4-1 ulp2*Δ, *cdc7-4 ulp2*Δ, and *cdc7-1 ulp2*Δ cells is rescued by expression of the *smt3-KRall* SUMO variant, which cannot form lysine-linked SUMO chains, as a single source of SUMO ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S6](#mmc1){ref-type="supplementary-material"}A).Figure 6Ulp2 Supports Efficient Replication Onset by Safeguarding MonoSUMOylated DDK Engaged in Replication(A and B) Synthetic lethality of *dbf4-1 ulp2*Δ and *cdc7-4 ulp2*Δ cells at permissive temperatures for *dbf4-1* and *cdc7-4* single mutants is suppressed by a lysine-less SUMO variant (*smt3-KRall*).(C) Reduced DDK-mediated Mcm4 phosphorylation in *ulp2*Δ cells is suppressed by deleting *SLX5*. Shown is IP of Mcm4^13MYC^ from exponentially growing WT, *slx5*Δ, *ulp2*Δ, and *ulp2*Δ *slx5*Δ cells. The specificity of the anti-Mcm4-phospho-S82-D83 antibody was evaluated by lambda phosphatase treatment (λ**)** with or without phosphatase inhibitors (Inh).(D) The SUMOylation-defective *ddk-KR* mutant rescues reduced DDK-dependent Mcm4 phosphorylation in *ulp2*Δ cells; as in (C), but Mcm4^13MYC^ IP from WT, *ddk-KR*, *ulp2*Δ, and *ulp2*Δ *ddk-KR* cells.(E) The decrease in BrdU incorporation in *ulp2*Δ cells is suppressed by *ddk-KR*, similar to *slx5*Δ. Shown is BrdU IP-on-chip analysis of cells released into S phase in the presence of 0.2 M HU and BrdU for 90 min after G1 arrest.(F) The S phase progression defect in *ulp2*Δ cells is suppressed by *ddk-KR*. Exponentially growing WT, *ddk-KR*, *ulp2*Δ, and *ulp2*Δ *ddk-KR* cells (cycl) arrested in G1 phase by α-factor were released into yeast extract-peptone-dextrose (YPD) media at 25°C, and samples were taken every 5 min for FACS.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

We then asked whether the function of Ulp2 in supporting early stages of replication ([Figure 2](#fig2){ref-type="fig"}) converges on the ability and/or availability of DDK to mediate Mcm4 phosphorylation, a modification required to initiate DNA replication ([@bib2], [@bib45]). To this end, we performed IP of Mcm4^13MYC^ and detected DDK-phosphorylated Mcm4 species using a phosphospecific antibody that recognizes phosphorylation of Mcm4-S82-D83, an intrinsic DDK target site ([@bib45]). Importantly, we found a reduction in DDK-mediated Mcm4 phosphorylation in *ulp2*Δ cells and suppression of this defect by the *slx5*Δ mutation ([Figure 6](#fig6){ref-type="fig"}C). We note that the signal for Mcm4 phosphorylation is higher in WT compared with *slx5*Δ and *ulp2*Δ *slx5*Δ cells, suggesting that Slx5 might positively influence DDK activity by targeting other substrates that, at the moment, remain unknown. We ascertained that the detected Mcm4 represents phosphorylated species by subjecting the IP material from WT cells to lambda phosphatase (λ) treatment in the absence or presence of phosphatase inhibitors (Inh). Thus, Ulp2 allows efficient Mcm4 phosphorylation.

To unambiguously link the unscheduled Slx5/8 STUbL-mediated proteasomal degradation of mono- and/or multiSUMOylated DDK to the replication defects observed in *ulp2*Δ cells, we sought to map the SUMO acceptor lysine residues on both Dbf4 and Cdc7 DDK subunits. Using the *cim3-1* background and a systematic mutagenesis approach to replace lysines (K) with arginines (R) in full-length 3HA-tagged Dbf4, we found, via Ni PD, that mutations in K6, K14, and K432 strongly reduced Dbf4 SUMOylation, with K432 being the major SUMO acceptor site ([Figure S6](#mmc1){ref-type="supplementary-material"}B). In parallel, we analyzed the published structure of the human DDK ([@bib24]) for exposed lysine residues conserved from yeast to humans that may lie within a SUMO consensus motif, ψ-K-x-E/D (ψ, a hydrophobic amino acid; x, any amino acid). We found that K16 in budding yeast Cdc7, corresponding to K41 in human Cdc7, meets these requirements and is a major SUMOylation site ([Figure S6](#mmc1){ref-type="supplementary-material"}C). K34 also contributes to Cdc7 SUMOylation to a minor extent ([Figure S6](#mmc1){ref-type="supplementary-material"}C), in addition to several other lysines, similar to the situation in human cells, where, using a high-throughput mass spectrometry approach, multiple SUMOylation sites have been mapped in DDK (see the list in [Figure S6](#mmc1){ref-type="supplementary-material"}C; [@bib22], [@bib31]). Thus, DDK SUMOylation is conserved from yeast to humans and targets a conserved site in Cdc7.

We next constructed a SUMOylation-defective *ddk-KR* mutant with mutations in the major Dbf4 and Cdc7 SUMOylation sites (*cdc7-K16R dbf4-K6R*, *K14R*, *K432R*) that does not need Ulp2 for protection. Importantly, the defect in DDK-mediated Mcm4 phosphorylation observed in *ulp2*Δ cells was rescued by the *ddk-KR* mutation, and the levels of phosphorylated Mcm4 were slightly increased in *ddk-KR* ([Figure 6](#fig6){ref-type="fig"}D). Moreover, the replication onset defect observed with BrdU incorporation in *ulp2*Δ cells was suppressed by *ddk-KR*, similar to *slx5*Δ ([Figure 6](#fig6){ref-type="fig"}E). Neither *ddk-KR* nor *slx5*Δ altered the replication origin usage profile. Finally, the slower S phase progression of *ulp2*Δ cells in unperturbed conditions was suppressed by the *ddk-KR* mutation ([Figure 6](#fig6){ref-type="fig"}F, 50--60 min), as it was by the *smt3-KRall* mutation ([Figure S6](#mmc1){ref-type="supplementary-material"}D, 45--60 min). Furthermore, we observed similar suppression of the replication initiation defect in *ulp2*Δ cells by the *ddk-KR* mutation under conditions that allow yeast cells to replicate DNA in G1 using the S-phase cyclin-dependent kinase (S-CDK) bypass setting ([Figure S6](#mmc1){ref-type="supplementary-material"}E). In S-CDK bypass cells, the essential function of S-CDK in replication initiation is being overcome by combining *sld3-dpb11* fusion with galactose-induced overexpression of a phosphomimetic *sld2-T84D* mutation ([@bib61]). Under such conditions, DDK becomes limiting for DNA replication, and ectopic overexpression of *DBF4* is necessary for extensive DNA synthesis in α-factor-arrested G1 cells ([@bib61]). In this S-CDK bypass system, the *ulp2*Δ mutation caused substantial delays in replication, whereas the *ddk-KR* mutation rescued this defect ([Figure S6](#mmc1){ref-type="supplementary-material"}E). Moreover, *ddk-KR* alone allowed a similar extent of DNA replication in G1 as *DBF4* overexpression or replacement of the chromosomal *MCM4* with *mcm4*^Δ*74--174*^ ([Figure S6](#mmc1){ref-type="supplementary-material"}E), an allele known to bypass the DDK requirement for replication initiation by alleviating inhibitory activity in Mcm4 ([@bib50]). These results indicate that Ulp2 facilitates replication onset by preventing unscheduled SUMO-chain-targeted Slx5/Slx8 STUbL-mediated degradation of mono- and/or multiSUMOylated DDK engaged in replication.

Slx5/8 Substrate Trapping and SILAC Screens Identify MCM Subunits and Other Replication Factors as Potential Targets of Ulp2 and Slx5/Slx8 {#sec2.7}
------------------------------------------------------------------------------------------------------------------------------------------

Our current knowledge of substrates regulated by the interplay between SUMO chains, Ulp2 protease, and Slx5/8 STUbL is very limited, and therefore we aimed to identify other potential targets of the regulatory timing mechanism uncovered here for DDK. To detect degradation-prone SUMOylated targets of the Slx5/8 STUbL, we decided to employ the ubiquitin ligase substrate-trapping approach ([@bib36]), which is based on fusion of the UBA domains derived from the Rad23 and Dsk2 ubiquitin receptors to the ubiquitin ligase under investigation, here Slx5/8 ([Figure S7](#mmc1){ref-type="supplementary-material"}A), in *ulp2*Δ *cim3-1* ^*His*^*SUMO* cells. Generated Slx8-UBA-domain fusions should bind ubiquitylated proteins in the vicinity of the Slx5/8 ubiquitin ligase, including its own substrates, when the ligase is catalytically active but not when it is inactivated by point mutations in the RING domain of Slx5 ([Figures 7](#fig7){ref-type="fig"}A and [S7](#mmc1){ref-type="supplementary-material"}B). Because both subunits of Slx5/Slx8-UBA additionally carry hemagglutinin (HA) tags, trapped ubiquitylated proteins can be co-immunoprecipitated together with other specific and unspecific Slx5/8 interactors in the first step of anti-HA IP and identified using mass spectrometry ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Because in most cases Slx5/8 targets substrates are marked by SUMO modifications, SUMOylated proteins are expected to be enriched by subsequent (second step) Ni PD of ^His^SUMO conjugates when Slx5/8 is catalytically active but not when it is inactivated and can only trap Slx5/8-independent ubiquitylated proteins, serving as a good indicator of the substrate-trapping specificity. It was indeed the case, as judged by western blot controls of the ligase substrate trapping with catalytically active stable Slx5/Slx8-UBA~Rad23~, highly unstable Slx5/Slx8-UBA~Dsk2~, and catalytically inactive stable Slx5-C561S,C564S/Slx8-UBA~Rad23~ substrate traps ([Figure S7](#mmc1){ref-type="supplementary-material"}D, samples 4--6). Interestingly, the utilized approach led to specific identification of the MCM helicase subunits and other replication factors that have been shown previously to be targeted by SUMO modification ([@bib12], [@bib59]) as potential substrates of the Slx5/8 STUbL ([Figure 7](#fig7){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}). Significantly fewer hits were identified following the second step Ni PD of ^His^SUMO conjugates ([Figure S7](#mmc1){ref-type="supplementary-material"}E), likely because of low protein amounts isolated, nevertheless confirming some of the potential Slx5/8 substrates from the first step, such as Sgs1 and Top2.Figure 7MCM Helicase and Other Replication Factors Are Potential Substrates of Ulp2 Protease and Slx5/8 STUbL(A) Slx5/Slx8-UBA STUbL substrate trapping from *cim3-1 ulp2*Δ cells. The Euler diagram shows proteins detected following IP with the indicated Slx5/Slx8-UBA substrate traps. Proteins ([Table S1](#mmc2){ref-type="supplementary-material"}) were identified using Scaffold with stringent criteria. Mcm7 (in parentheses) was detected with one unique peptide. Tup1 (in italics) is a validated SUMOylated Slx5/8 substrate.(B) Outline of the SILAC experiment aiming to detect degradation-prone SUMOylated substrates that decrease in abundance in a SUMO-chain-dependent manner in *ulp2*Δ *cim3-1* cells (left). SILAC ratios for 726 quantified proteins were plotted against the sum of the relevant peptide intensities (right). MCM subunits and replication factors detected by Slx5/8 ligase substrate trapping in (A) are colored red.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

We aimed to complement the aforementioned findings by searching for degradation-prone SUMO conjugates that decrease in abundance in the absence of Ulp2 specifically in a SUMO-chain-dependent manner, as is the case for DDK ([Figures 4](#fig4){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}B). Therefore, we compared, by ^His^SUMO Ni PD using a SILAC-based mass spectrometry approach ([@bib34]), the levels of SUMO conjugates in *ulp2*Δ *cim3-1* mutants expressing either the WT or the *KRall* SUMO variant ([Figure 7](#fig7){ref-type="fig"}B, left). This screen quantified 726 potential SUMO conjugates ([Figure 7](#fig7){ref-type="fig"}B, right); the abundance of most of them did not change significantly (e.g., proliferating cell nuclear antigen \[PCNA\] or Pol30 in yeast), whereas SUMO conjugates pulled down from the *KRall* mutant were more abundant in general (Smt3; [Figure 4](#fig4){ref-type="fig"}B, Ni PD). Strikingly, among the SUMO substrates strongly enriched in the sample derived from SUMO-chainless *ulp2*Δ cells were, again, MCM subunits and other replication factors ([Figure 7](#fig7){ref-type="fig"}B, right) identified earlier by Slx5/8 ligase substrate trapping ([Figure 7](#fig7){ref-type="fig"}A). Importantly, we also found the known SUMOylated Ulp2 substrates Net1, Tof2, Cdc14, and Tup1 ([@bib32]) and the confirmed Slx5/8 targets Cse4, Tof2, and Tup1 ([@bib32], [@bib41], [@bib58]) to decrease in abundance in *ulp2*Δ cells depending on SUMO chains. The presence of these previously reported hits and overlap between the two screens highlight the MCM helicase as a likely substrate of SUMO-chain-targeted Slx5/Slx8 STUbL-mediated degradation regulated by Ulp2. Because MCM is extracted and degraded during replication termination in an SCF(Dia2)-mediated manner ([@bib35]), and *slx5*Δ and *dia2*Δ mutations are synthetic lethal ([Figure S7](#mmc1){ref-type="supplementary-material"}F; [@bib5]), it is possible that SUMO-chain- and Slx5/8-mediated degradation might operate during replication termination as a backup pathway for SCF(Dia2)-mediated replisome disassembly, which targets Mcm7. In all, we propose SUMO-chain/Ulp2-protease-regulated proteasomal degradation to act as a mechanism that times the availability of functionally engaged SUMO-modified protein pools during replication.

Discussion {#sec3}
==========

Here we uncovered that the SUMO protease Ulp2, controlling the physiological extent of SUMO conjugation, serves as a guardian against unscheduled SUMO chain assembly on DDK, timing its proteasomal degradation. This action of Ulp2, likely also involving MCM subunits, allows replication initiation and may have other functions beyond replication by means of other substrates. We propose that SUMO chains regulated by the Ulp2 protease function like a countdown timer when they are assembled on the substrates of STUbLs, which may channel them either for degradation or equip them with other functional properties of the ubiquitin code.

Our findings indicate that Ulp2 interacts and cooperates with DDK to support replication onset. DDK becomes SUMOylated with single SUMO moieties (monoSUMOylation) at multiple sites (multiSUMOylation) when the kinase engages in replication and is bound to chromatin. However, monoSUMOylation can be extended to SUMO chains, which can recruit STUbLs and mediate proteasomal degradation of the modified substrate. Indeed, we find that specifically SUMO chains promote Slx5/8 STUbL-mediated and Cdc48 segregase-assisted proteasomal degradation of SUMOylated DDK when not protected by Ulp2. Loss of Ulp2 causes defects in MCM activation and replication onset. Notably, these replication defects are suppressed by a SUMOylation-defective *ddk-KR* mutant that no longer requires Ulp2 for protection against Slx5/8 STUbL. Moreover, *ddk-KR* also allows yeast cells to replicate DNA under the S-CDK bypass condition, when DDK becomes limiting for DNA replication in G1-arrested cells ([@bib61]), because of APC/C-Cdc20-mediated proteasomal destruction of Dbf4 in M/G1 ([@bib9], [@bib17]). Thus, Ulp2 facilitates replication onset by preventing unscheduled SUMO-chain-targeted Slx5/8 STUbL-mediated degradation of the mono- and/or multiSUMOylated DDK pool engaged in replication.

We note that the SUMO-chain/Ulp2 protease-mediated timing of proteasomal degradation uncovered here is fundamentally different in significance from the previously described APC/C-mediated Dbf4 destruction mechanism. Although APC/C-mediated degradation limits Dbf4 protein levels in M/G1 to prevent unscheduled replication ([@bib9], [@bib17]), Ulp2 engages and stabilizes mono- and/or multiSUMOylated DDK functionally engaged in replication, allowing efficient replication onset. At the same time, SUMOylation marks the active DDK pool for subsequent SUMO-chain-targeted proteasomal turnover, potentially to prevent re-replication and to facilitate replication termination at a time when Ulp2 is no longer concentrated in the proximity of DDK or becomes inhibited by the Cdc5 kinase in mitosis ([@bib1]).

SUMOylation has been proposed to happen in waves that affect functional protein groups ([@bib27]). In the context of double-strand break repair, protein group SUMOylation fosters interactions between multiple homologous recombination factors, making the repair process more efficient ([@bib43]). Similar SUMOylation waves are envisaged to happen in other cellular settings, one of which may be replication initiation. Indeed, many replisome components loaded at origins of replication, including -- origin recognition complex (ORC) and MCM, are SUMOylated ([@bib12], [@bib21], [@bib59]). Here, using two proteomic approaches, we identify MCM subunits and several replication factors along with other previously reported groups, such as the ones implicated in ribosomal DNA silencing ([@bib32]), as potential substrates of both Ulp2 and Slx5/8, channeled for proteasome-mediated degradation in a SUMO-chain-dependent fashion. Thus, enrichment of Ulp2 at origins of replication is likely coupled with the wave of SUMOylation occurring during replication initiation to preserve replication-engaged factors that can be recognized by STUbLs until their turnover is scheduled. The MCM helicase has been found to be extracted from chromatin by the Cdc48 segregase during replication termination upon its ubiquitylation by the SCF(Dia2) ubiquitin ligase ([@bib35], [@bib38]) but also appears to be degraded in a Slx5/8- and SUMO-chain-dependent manner. Because mutations in Dia2 are synthetic lethal with loss of Slx5/8, it is possible that the SCF(Dia2) and Slx5/8 SUMO chain pathways act in compensation to promote degradation of replication proteins, such as MCM, before activation of anaphase-promoting complex/cyclosome (APC/C) in mitosis.

How exactly Slx5/8 STUbL recognizes its targets is not well understood, but because all SUMOylated factors can potentially undergo SUMO chain assembly, whereas only a few Slx5/8 substrates are known, it is likely that a specific degradation signal (degron) is additionally present in polySUMOylated substrates that undergo Slx5/8-dependent turnover. Moreover, Ulp2 and Slx5/8 STUbL seem to share several substrates. From this perspective, our identification of DDK as a substrate of both Ulp2 and Slx5/8 makes it a good study case for future mapping of the Slx5/8 degron and the Ulp2 recruitment motif.

In conclusion, our work provides mechanistic insights into how dynamic SUMO modification of DDK and other replication factors at replication origins cooperate with the SUMO-chain-editing protease Ulp2 *in vivo* to allow chromosome replication onset, highlighting an important function of SUMO chain signaling in the replication initiation context and opening ways to address other unsolved puzzles in the SUMO pathway.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse monoclonal anti-FLAG antibody (clone M2) (Dilution for western blot 1:2000)Sigma-AldrichCat\# F1804; RRID: [AB_262044](nif-antibody:AB_262044){#intref0010}Mouse monoclonal anti-Viral V5-TAG antibody (clone SV5-Pk1) (Dilution for western blot 1:5000)Bio-Rad / AbD SerotecCat\# MCA1360; RRID: [AB_322378](nif-antibody:AB_322378){#intref0015}Mouse monoclonal anti-Pgk1 antibody (clone 22C5D8) (Dilution for western blot 1:2000)Thermo Fisher ScientificCat\# 459250; RRID: [AB_2532235](nif-antibody:AB_2532235){#intref0020}Mouse monoclonal anti c-MYC antibody (clone 9E10) (Dilution for western blot 1:2000)In houseN/AMouse monoclonal anti-Rad53 antibody (clone EL7) (Dilution for western blot 1:5)In house ([@bib18])N/ARabbit polyclonal anti-GST antibody (Dilution for western blot 1:3000)In houseN/AMouse monoclonal anti-HA (F-7) antibody (Dilution for western blot 1:2000)Santa Cruz BiotechnologyCat\# sc-7392; RRID: [AB_627809](nif-antibody:AB_627809){#intref0025}Mouse monoclonal anti-Bromodeoxyuridine antibody (clone 2B1)MBL InternationalCat\# MI-11-3; RRID: [AB_590678](nif-antibody:AB_590678){#intref0030}Rabbit polyclonal anti-Ubiquitin antibody (Dilution for western blot 1:2000)AbcamCat\# ab19247; RRID: [AB_444805](nif-antibody:AB_444805){#intref0035}Rabbit polyclonal anti-Clb2 (y-180) antibody (Dilution for western blot 1:2000)Santa Cruz BiotechnologyCat\# sc-9071; RRID: [AB_667962](nif-antibody:AB_667962){#intref0040}Rabbit polyclonal anti-Smt3 (y-84) antibody (Dilution for western blot 1:2000)Santa Cruz BiotechnologyCat\# sc-28649; RRID: [AB_661135](nif-antibody:AB_661135){#intref0045}Rabbit polyclonal anti-SUMO2/3 antibody (Dilution for western blot 1:2000)AbcamCat\# ab3742; RRID: [AB_304041](nif-antibody:AB_304041){#intref0050}Rabbit polyclonal anti-Mcm2-7 (UM185) antibody (Dilution for western blot 1:5000)Gift from Stephen P. Bell ([@bib6])N/ARabbit polyclonal anti-Mcm4-phospho-S82-D83 antibody (Dilution for western blot 1:400)Gift from Stephen P. Bell ([@bib45])N/AAnti-HA affinity matrix; (clone 3F10) rat monoclonal antibodyRocheCat\# 11815016001; RRID: [AB_390914](nif-antibody:AB_390914){#intref0055}Anti-rabbit IgG, HRP-linked antibody (Dilution for western blot 1:5000)Cell Signaling TechnologyCat\# 7074; RRID: [AB_2099233](nif-antibody:AB_2099233){#intref0060}Anti-mouse IgG, HRP-linked antibody (Dilution for western blot 1:5000)Cell Signaling TechnologyCat\# 7076; RRID: [AB_330924](nif-antibody:AB_330924){#intref0065}Normal mouse IgGSanta Cruz BiotechnologyCat\# sc-2025; RRID: [AB_737182](nif-antibody:AB_737182){#intref0070}**Chemicals, Peptides, and Recombinant Proteins**alpha-factor mating pheromone (WHWLQLKPGQPMY)GenScript; RRID: [SCR_002891](rridsoftware:SCR_002891){#intref0075}Cat\# 59401-28-4Recombinant human poly-SUMO3 wild-type K-11-linked chains (2-8)Boston BiochemCat\# ULC-310Recombinant budding yeast N-terminally His-tagged wild-type SUMO (^His^SUMO)In houseN/ARecombinant glutathione S-transferase (GST) and GST-Ulp2 fusion proteins (amino acids 1-400, wild-type or with mutated SUMO-interacting motifs)In houseN/ANocodazoleSigma-AldrichCat\# M1404ImidazoleSigma-AldrichCat\# I2399HydroxyureaSigma-AldrichCat\# H8627BromodeoxyuridineSigma-AldrichCat\# B9285Ni-NTA agaroseQIAGENCat\# 30210Recombinant protein G -- Sepharose 4BThermo Fisher ScientificCat\# 101243Glutathione Sepharose 4BGE HealthcareCat\# 17-0756-01Dynabeads protein AThermo Fisher ScientificCat\# 10002DcOmplete, EDTA-free protease inhibitor cocktail tabletsRocheCat\# 4693132001N-EthylmaleimideSigma-AldrichCat\# E3876Phenylmethanesulfonyl fluorideSigma-AldrichCat\# P7626IodoacetamideSigma-AldrichCat\# I1149Phosphatase inhibitor cocktail 2Sigma-AldrichCat\# P5726Phosphatase inhibitor cocktail 3Sigma-AldrichCat\# P0044Zymolyase 100T (Arthrobacter luteus)Seikagaku CorporationCat\# 120493Lambda protein phosphataseNew England BiolabsCat\# P0753SRibonuclease A from bovine pancreasSigma-AldrichCat\# R5503Proteinase K, recombinant, PCR GradeRocheCat\# 031158010014,5′,8-TrimethylpsoralenSigma-AldrichCat\# T6137Agarose D1-LEFisher Molecular BiologyCat\# AS-101**Critical Commercial Assays**GenomePlex complete whole genome amplification (WGA) kitSigma-AldrichCat\# WGA2GenomePlex WGA reamplification kitSigma-AldrichCat\# WGA3QuantiFast SYBR Green PCR kitQIAGENCat\# 204054Genomic-tip 100/GQIAGENCat\# 10243QIAquick PCR purification kitQIAGENCat\# 28106ProbeQuant G-50 micro columnsGE HealthcareCat\# 28903408Prime-a-Gene labeling systemPromegaCat\# U1100Invitrogen Bolt 4-12% Bis-Tris Plus Gels, 15-wellThermo Fisher ScientificCat\# NW04125BOXL-Arginine:HCl (U-13C6, 99%; U-15N4, 99%)Cambridge Isotope LaboratoriesCAS\# 1119-34-2CNLM-539-H-0.25L-Lysine:2HCl (U-13C6, 99%; U-15N2, 99%)Cambridge Isotope LaboratoriesCAS\# 657-26-1CNLM-291-H-0.25**Deposited Data**Raw and analyzed ChIP-on-chip and BrdU IP-on-chip dataThis paperGEO: [GSE113835](ncbi-geo:GSE113835){#intref0080}**Experimental Models: Organisms/Strains**All yeast Saccharomyces cerevisiae strains used in this work, except those used for yeast two-hybrid (Y2H) studies, are W303 background derivatives with the wild type *RAD5* locus. They are listed in [Table S2](#mmc3){ref-type="supplementary-material"}.This paperN/AY2HGold yeast strainTakaraCat\# 630498**Oligonucleotides**Primer ARS305F for qPCR: CTCCGTTTTTAGCC\
CCCGTGThis paperN/APrimer ARS305R for qPCR:This paperN/AGATTGAGGCCACAGCAAGACCG**Recombinant DNA**A6C-110[@bib40]N/ApGAD-C1, pGBD-C1[@bib25]N/ApGEX-6P-2GE HealthcareCat\# 28-9546-50**Software and Algorithms**Affymetrix Tiling Analysis SoftwareThermo Fisher Scientific<https://www.thermofisher.com/us/en/home/life-science/microarray-analysis/microarray-analysis-instruments-software-services/microarray-analysis-software/tiling-array-tools.html>UCSC Genome Browser[@bib28]<https://genome.ucsc.edu/>CEAS (Cis-regulatory Element Annotation System) package sitepro script[@bib51]<http://liulab.dfci.harvard.edu/CEAS/download.html>Cytobank[@bib30]<https://www.cytobank.org/>MaxQuant (version 1.5.2.8)[@bib11]<https://www.biochem.mpg.de/5111795/maxquant>Scaffold[@bib48]<http://www.proteomesoftware.com/products/scaffold/>**Other**ULTImate yeast two-hybrid **(**Y2H) screenHybrigenics Services<https://www.hybrigenics-services.com/>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dana Branzei (<dana.branzei@ifom.eu>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Yeast Strains {#sec4.3.1}

Chromosomally tagged *Saccharomyces cerevisiae* strains and mutants were constructed by a PCR-based strategy, by genetic crosses and standard techniques ([@bib26]). Standard cloning and site-directed mutagenesis techniques were used. Strains and all genetic manipulations were verified by polymerase chain reaction (PCR), sequencing and phenotype. Maps and primer DNA sequences are available upon request. All yeast strains used in this work except those used for the yeast two-hybrid (Y2H) studies are isogenic to W303 background and are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}.

Method Details {#sec4.4}
--------------

### Yeast Techniques {#sec4.4.1}

Yeast cultures were inoculated from overnight cultures, grown using standard growth conditions and media ([@bib49]). All cultures were grown in YPD-media containing glucose (2%) as carbon source at 28°C unless otherwise indicated. For cell cycle synchronization, logarithmic cells grown at 28°C were arrested in G1 using 3-5 μg/ml of alpha-factor for 2-3 hours. G2 arrest was performed with 20 μg/ml of nocodazole for 2-3 hours. G1/G2-arrest was verified microscopically and by FACS analysis. Hydroxyurea (HU) was used at the concentration of 200 mM, bromodeoxyuridine (BrdU) at 200 μg/ml. For drug sensitivity assays, cells from overnight cultures were counted and diluted before being spotted on YPD plates containing the indicated concentrations of HU and incubated at 28°C for 2-3 days. The ULTImate Y2H screen using full-length Ulp2 (N-GAL4-ULP2-C fusion) as bait was performed by Hybrigenics Services. For further Y2H analysis *CDC7*, *DBF4* and different truncations/mutants of *ULP2* were cloned into pGAD-C1 or pGBD-C1 vectors and cotransformed into Y2HGold yeast strain. Standard cloning and site-directed mutagenesis techniques were used. Maps and primer DNA sequences are available upon request.

### TCA Protein Precipitation {#sec4.4.2}

To preserve the post-translational modifications, yeast cells were lysed under denaturing conditions. For preparation of denatured protein extracts, yeast cultures grown to an OD~600~ = 0.7-1 were pelleted by centrifugation (4000 rpm, 4 min, 4°C) and immediately frozen in liquid nitrogen. After thawing on ice, the pellets were lysed by addition of denaturing lysis buffer (1.85 M NaOH, 7.5% β-mercaptoethanol) for 15min on ice. For the cell pellet of an OD~600~ = 1 typically 150 μL of lysis buffer was used. To precipitate the proteins, the lysate was subsequently mixed with an equal volume (150 μL in case of OD~600~ = 1) of 55% (w/v) trichloroacetic acid (TCA) and further incubated on ice for 15 min. The precipitated material was recovered by two sequential centrifugation steps (13000 rpm, 4°C, 15 min). Pelleted denatured proteins were then either directly resuspended in HU sample buffer (8 M urea, 5% SDS, 1 mM EDTA, 1.5% DTT, 1% bromophenol blue; 50 μL per OD~600~ = 1), boiled for 10 min and stored at −20°C, or used for downstream processing, e.g., Ni-NTA pull-downs of His-tagged SUMO conjugates.

### Ni-NTA Pull-down of ^His^SUMO Conjugates {#sec4.4.3}

For isolation of *in vivo* SUMOylated substrates from yeast cells expressing N-terminally His-tagged Smt3 (^His^SUMO), denatured protein extracts were prepared and Ni-NTA chromatography was carried out as described previously ([@bib43], [@bib44]). In general, 200 OD~600~ = 1 of logarithmically growing cells were harvested by centrifugation (4000 rpm, 4 min, 4°C), washed with pre-chilled water, transferred to 50 mL falcon tube and lysed with 6 mL of 1.85 M NaOH / 7.5% β-mercaptoethanol for 15 min on ice. The proteins were precipitated by adding 6 mL of 55% TCA and another 15 min incubation on ice (TCA-precipitation, described above). Next, the precipitate was pelleted by centrifugation (3500 rpm, 15 min, 4°C), washed twice with water and finally resuspended in buffer A (6 M guanidine hydrochloride, 100 mM NaH~2~PO~4~, 10 mM Tris-HCl, pH 8.0, 20 mM imidazole) containing 0.05% Tween-20. After incubation for 1 hour on a roller at room temperature with subsequent removal of insoluble aggregates by centrifugation (23000 g, 20 min, 4°C), the protein solution was incubated overnight at 4°C with 50 μL of Ni-NTA agarose beads in the presence of 20 mM imidazole. After incubation, the beads were washed three times with buffer A containing 0.05% Tween-20 and five times with buffer B (8 M urea, 100 mM NaH~2~PO~4~, 10 mM Tris-HCl, pH 6.3) with 0.05% Tween-20. ^His^SUMO conjugates bound to the beads were finally eluted by incubation with 50 μL of HU sample buffer for 10 min at 65°C. Proteins were resolved on precast Bolt 4%--12% Bis-Tris Plus gradient gels, and analyzed by standard western blotting techniques using antibodies listed in the [Key Resources Table](#sec4.1){ref-type="sec"}.

### Immunoprecipitation and Phosphatase Treatment {#sec4.4.4}

For the immunoprecipitation (IP), IPs followed by lambda protein phosphatase treatment, and binding studies involving co-IP, native yeast extracts were prepared by cell disruption using grinding in liquid nitrogen. To avoid protein degradation and loss of PTMs, lysis buffer (150 mM NaCl, 10% glycerol, 1% NP-40, 50 mM Tris HCl, pH 8.0) was supplemented with inhibitors: EDTA-free complete cocktail, 20mM N-ethylmaleimide, 1 mM phenylmethanesulfonyl fluoride (PMSF), 25 mM iodoacetamide, and phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich). For IPs, anti-PK, anti-FLAG, or anti-MYC antibodies, together with recombinant protein G Sepharose 4B beads, or anti-HA affinity matrix alone were used. IPs were performed overnight with head-over-tail rotation at 4°C and were followed by stringent washing steps to remove non-specific background binding to the beads. For protein dephosphorylation, lambda protein phosphatase was used to treat IP samples following Sepharose bead washing according to manufacturer's instructions, and was either supplemented with phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich) to inactivate the phosphatase or not.

### GST *in vitro* pull-down assays {#sec4.4.5}

The N terminus of Ulp2 (aa 1-400) either wild-type or with different SIMs mutated (Ulp2-V60A,L61A,L200A,L201A,L206A,I207A,I208A, termed Ulp2-sim1,2,3; Ulp2-V60A,L61A,L200A,L201A,L206A,I207A,I208A,I229A,L230A,I276A,L277A, termed Ulp2-sim1,2,3,4,5) was cloned into pGEX-6P-2 (GE Healthcare) vector, and Rosetta(DE3) pLysS competent *E. coli* cells (Novagen) were used for GST-fusion protein expression. Following overnight protein induction with 0.25 mM IPTG at 16°C in 500 mL cell cultures, cells were pelleted, resuspended in 30 mL lysis buffer (1X PBS, 500 mM NaCl, 1% Triton X-100, lysozyme, Calbiochem EDTA-free protease inhibitor cocktail set III) and sonicated on ice. The crude lysate was clarified by centrifugation at 15000 rpm for 15 min at 4°C, and the supernatant was mixed with 0.2 mL of glutathione Sepharose 4B beads (GE Healthcare) pre-equilibrated with lysis buffer. Following overnight incubation at 4°C, five washes with lysis buffer were performed and the beads with bound GST-fusion proteins were used for subsequent *in vitro* pull-down assays with recombinant yeast N-terminally His-tagged Smt3 and human poly-SUMO3 wild-type chains (2-8 moieties) from BostonBiochem. The amounts of GST-fusion proteins bound to the beads were estimated by comparison to the BSA samples of known concentrations resolved by SDS-PAGE and Coomassie Blue staining. To study the interaction between GST-Ulp2~1-400~ fusions and SUMO, either purified recombinant His-tagged yeast Smt3 (2.5 μg) or recombinant human poly-SUMO3 wild-type (2-8 moieties) chains (2.5 μg) were incubated either with GST-Ulp2~1-400~ (2.5 μg) and its SIM mutant variants, or GST (2.5 μg) alone bound to glutathione Sepharose 4B beads in 0.7 mL of binding buffer (1X PBS, 150 mM NaCl, 1% Triton X-100, Calbiochem EDTA-free protease inhibitor cocktail set III) overnight at 4°C, with gentle mixing. After the incubation, the beads were washed 5 times with 1 mL of the binding buffer and bound proteins were eluted with 50 μL of HU sample buffer. Samples were then analyzed by SDS-PAGE followed by western blotting and probing with anti-Smt3, anti-SUMO2/3 and anti-GST antibodies, and subsequent staining of the membrane with Ponceau S.

### ChIP, ChIP-on-chip, BrdU IP-on-chip {#sec4.4.6}

Chromatin immunoprecipitation (ChIP) was carried out as previously described ([@bib4]). Briefly, cells were collected at the indicated experimental conditions and crosslinked with 1% formaldehyde for 15-30 min. Cells were washed twice with ice-cold 1X TBS, suspended in lysis buffer supplemented with 1 mM PMSF and 1X EDTA-free complete cocktail, and lysed using FastPrep-24 (MP Biomedicals). Chromatin was sheared to a size of 300-500 bp by sonication. IP reactions, with anti-FLAG or anti-PK antibodies and Dynabeads protein A, were allowed to proceed overnight at 4°C. After washing and eluting the ChIP fractions from beads, crosslinks were reversed at 65°C overnight for both SUP and IP. After proteinase K treatment, DNA was extracted twice by phenol/chlorophorm/isoamyl alcohol (25:24:1, v/v). Following precipitation with ethanol and Ribonuclease A (RNase A) treatment, DNA was purified using QIAquick PCR purification kit. For ChIP-on-chip, DNA was then amplified using GenomePlex complete whole genome amplification (WGA) kits WGA2 and WGA3 following manufacturer's instructions. 4 μg of DNA from SUP and IP samples were hybridized to GeneChip *S. cerevisiae* Tiling 1.0R Array (Affymetrix). For the BrdU IP experiments, the genomic DNA extraction was performed using the Genomic-tip 100/G columns, followed by sonication to shear the DNA to a size of 300-500 bp. The IP of the BrdU-containing DNA was performed using the anti-BrdU antibody.

### ChIP-qPCR {#sec4.4.7}

ChIP-qPCR was performed using QuantiFast SYBR Green PCR kit according to the manufacturer's instructions and each reaction was performed in triplicates using a Roche LightCycler 480 system. The results were analyzed with absolute quantification/2^nd^ derivative maximum and the 2(-ΔC(t)) method as previously described ([@bib33]). Error bars represent standard deviations.

### 2D Gel Electrophoresis {#sec4.4.8}

Cells were synchronized in G1 phase with alpha-factor at 28°C and released in media containing HU 0.2 M. Samples were collected at the indicated time points and incubated with sodium azide 1% for 30 min on ice. *In vivo* psoralen crosslinking and DNA extraction with CTAB were performed as in [@bib20]. Briefly, cells were washed, resuspended in 5ml of cold water in small Petri dishes and kept on ice. 300 μL of 4,5′,8-trimethylpsoralen solution (0.2 mg/ml in EtOH 100%) was added prior to extensive resuspension by pipetting, followed by 5 min of incubation in the dark and then 10 min of UV irradiation at 365 nm (Stratagene UV Stratalinker 2400). The procedure was repeated 3 times to ensure extensive crosslinking. Cells were then harvested by centrifugation, washed in cold water, and incubated in spheroplasting buffer (1M sorbitol, 100 mM EDTA, 0.1% β-mercaptoethanol, and 50 U zymolyase/ml) for 1.5 h at 30°C. In all, 2 mL water, 200 μL RNase A (10 mg/ml), and 2.5 mL Solution I (2% w/v cetyltrimethylammonium bromide (CTAB), 1.4 M NaCl, 25 mM EDTA, 100 mM Tris--HCl, pH 7.6) were sequentially added to the spheroplast pellets and samples were incubated for 30 min at 50°C. 200 mL Proteinase K (20 mg/ml) was then added and the incubation was prolonged at 50°C for 90 min, and at 30°C overnight. The sample was then centrifuged at 4000 rpm for 10 min: the cellular debris pellet was kept for further extraction, while the supernatant was extracted with 2.5 mL chloroform/isoamylalcohol (24:1) and the DNA in the upper phase was precipitated by addition of 2 volumes of Solution II (1% w/v CTAB, 10 mM EDTA, 50 mM Tris--HCl, pH 7.6) and centrifugation at 8500 rpm for 10 min. The pellet was resuspended in 2 mL Solution III (1.4 M NaCl, 1 mM EDTA, 10 mM Tris--HCl, pH 7.6). Residual DNA in the cellular debris pellet was also extracted by resuspension in 2ml Solution III and incubation at 50°C for 30 min, followed by extraction with 1 mL chloroform/isoamylalcohol (24:1). The upper phase was pooled together with the main DNA prep. Total DNA was then precipitated with 1 volume of isopropanol, washed with 70% ethanol, air-dried, and finally resuspended in 1x TE. Alternatively, DNA can be extracted following the QIAGEN protocol for the purification of yeast genomic DNA using the Genomic-tip 100/G columns. Subsequently, 10 μg of DNA were digested with the indicated restriction endonucleases, precipitated with potassium acetate and isopropanol, and resuspended in 10mM Tris-HCl, pH 8.0. Digested genomic DNA was run on the Thermo Scientific Owl A2 large gel system (gel tray 27x20 cm) filled with 2.5 l of 1x TBE. The first dimension gel (500 ml; 0.35% w/v Agarose D1-LE) was prepared with 1x TBE and run at 50 V for 24 hours at room temperature. The second dimension gel (500 ml; 0.9% w/v Agarose D1-LE) prepared with 1x TBE was run in the same electrophoresis chamber at 150 V for 12 hours at 4°C with current limited to 150 mA. DNA molecules separated on the second dimension gels were transferred onto nylon filters via Southern blotting following standard procedures. Signals were detected using a probe against *ARS305* (BamHI-NcoI 3.0 kb fragment that spans ARS305 and was purified from plasmid A6C*-*110) radiolabelled according to the protocol of the Prime-A-Gene labeling system and purified with ProbeQuant G-50 micro columns.

### FACS Analysis {#sec4.4.9}

For flow cytometry analysis, approximately 7x10^6^ cells for each time-point were collected, washed in sterile water, and permeabilized in 70% ethanol at 4°C overnight. Cells were suspended in 10 mM Tris pH 7,5 buffer, and RNA together with proteins were removed by RNase A (0,4 mg/ml final concentration) and proteinase K (1 mg/ml) treatment. Subsequently, cells were stained with PI (propidium iodide 50 μg/ml). Cell cycle profiles were obtained following a brief sonication using a Becton Dickinson FACSCalibur system. Acquired data was analyzed with Cytobank.

### Mass Spectrometry {#sec4.4.10}

For the detection of degradation-prone SUMO conjugates decreased in abundance in *ulp2*Δ *cim3-1* mutant cells specifically in a SUMO-chain-dependent manner ([Figure 7](#fig7){ref-type="fig"}B), SILAC-based mass spectrometry protocol ([@bib34]) was used. Yeast *ulp2*Δ *cim3-1* mutant cells deficient in biosynthesis of lysine and arginine (*lys1*Δ and *arg4*Δ) expressing either wild-type His-tagged SUMO (^His^SUMO) or its lysine-less variant (*KRall*) that cannot form lysine-linked polySUMO chains were grown for at least ten divisions in synthetic complete media supplemented either with unlabeled (Lys0 and Arg0; light) or heavy isotope-labeled amino acids (Lys8 and Arg10; heavy) from Cambridge Isotope Laboratories. Exponentially dividing ^*His*^*SUMO ulp2*Δ *cim3-1* cells grown in heavy media were harvested, combined with equal amount of *KRall ulp2*Δ *cim3-1* cells grown in light media, and SUMO conjugates were isolated by using denaturing Ni-NTA pull-down. Proteins isolated following Slx5/8 ubiquitin ligase substrate trapping ([@bib36]) and denaturing Ni-NTA pull-downs of ^His^SUMO conjugates were separated on 4%--12% Bis-Tris gel. The whole lane was excised in slices and proteins were digested with trypsin. Extracted peptides were analyzed by LC-MS/MS using the Q Exactive HF mass spectrometer and identified by either using MaxQuant ([@bib11]) or Scaffold ([@bib48]) software. Proteins identified using Scaffold with stringent criteria (the minimum protein probability -- 99%; the minimum number of unique peptides -- 2; the minimum peptide probability -- 95%) are listed in [Table S1](#mmc2){ref-type="supplementary-material"}, related to [Figures 7](#fig7){ref-type="fig"}A and [S7](#mmc1){ref-type="supplementary-material"}E.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Analysis of ChIP/BrdU IP-on-chip Data {#sec4.5.1}

CEL files obtained by scanning of the hybridized Affymetrix chips were analyzed using a modified version of the Tiling Array Suite (TAS) software from Affymetrix as previously described ([@bib4]). Briefly, the software performs a linear scale normalization of input CEL files (IP and SUP) intensity so that the median value is equal to a selected target intensity of 500. Signals and the p value changes obtained from TAS per each probe position are subsequently used by the software to detect clusters of enriched signals as ranges within the chromosomes. Conditions for clusters detection in whole range (at least 600 bps), except for segments within the range shorter than 600 bps, were: log2 signal (IP/SUP binding ratio) positive and change in p value (evaluated using Wilcoxon signed-rank test) less than 0.2. The peak of each cluster has been defined as the genomic position within the cluster with the highest estimated signal. All the clusters identified for all datasets produced in the work are available upon request as BED tracks suitable for visualization on the UCSC genome browser. Evaluation of the significance of protein binding/BrdU-incorporation cluster distributions within the different genomic areas (e.g., origins of replication, ARSs) and the significance of the overlap between clusters was performed by confrontation to the model of the null hypothesis distribution generated by a Monte Carlo-like simulation as previously described ([@bib4]). Briefly, for each pair of datasets (protein binding/BrdU-incorporation clusters and a given genomic area, e.g., early origins of replication) 1000 randomizations of the positions of the genomic ranges were produced, while maintaining the following conditions at each randomization. First, the number and sizes of all the genomic areas covered within each chromosome remain the same. Second, the genomic areas are positioned in a safely random manner on the chromosome, ensuring that they do not overlap with each other. For each randomized set, the number of peaks falling within the ranges was counted and taken as a random score of the model. The distribution of random scores was validated to be approximately normal and then the average and standard deviation for the random model was taken as null hypothesis. The increase or decrease ratio for the scores of the actual positions of clusters with respect to the expected value for the null hypothesis (the average score of random attempts) was then calculated, and the p value for the drift was estimated as the cumulative distribution function of the standard normal distribution. The significance of overlap between the protein binding/BrdU-incorporation clusters (e.g., Ulp2 clusters versus BrdU-incorporation clusters) was performed following the same logic used to validate the distribution in the different genomic areas with one difference. The "score" for both the randomized positions and the actual data was calculated as the total number of overlapping bases among the whole clusters. Using the number of overlapping bases introduces a linear dependency of the obtained score from the average size of the clusters, which happens in both the randomized sets and the actual one and thus cancelled for the purpose of the simulation. Furthermore, in this case, the randomization is performed twice: once for each set, and results are evaluated independently in order to assess if there is any bias introduced by the structure of the two covered areas (sizes and spacing between the covered ranges).

### Average Binding/BrdU-incorporation Profiling {#sec4.5.2}

Average profiling of the chromatin binding and BrdU incorporation signals within specific genomic loci was obtained using the sitepro script of CEAS (Cis-Regulatory Element Annotation System) package ([@bib51]). Briefly, log2 signal (IP/SUP binding ratio) BED files obtained from the chromatin binding/BrdU incorporation analyses were converted to WIG files and used to draw the average signals around specific genomic loci, e.g., 141 active ARSs (origins of replication) as in [@bib47], setting 50 bps as the profiling resolution and varying sizes (1.5-22 kbps) of flanking regions from the center of each specific genomic loci. For the calculation of average chromatin binding/BrdU incorporation signals, negative values were either taken unchanged or set to zero.

Data and Code Availability {#sec4.6}
--------------------------

The accession number for the microarray data reported in this paper is Gene Expression Omnibus (GEO): [GSE113835](ncbi-geo:GSE113835){#intref0125}.
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